Current Report Filing (8-k)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
Date of Report (Date of earliest event reported): April 21,
REGEN BIOPHARMA, INC.
(Exact name of small business issuer as specified in its
or other jurisdiction of incorporation or organization)
Employer Identification No.)
Commission File No. 333-191725
711 S. Carson Street, Suite 4, Carson City, Nevada,
(Address of Principal Executive Offices)
(619) 722 5505
(Issuer’s telephone number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act (17
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
8.01 Other Events.
On April 21, 2021 Regen Biopharma, Inc. (the “Company”) sold
10,000 common shares of Oncology Pharma, Inc. to an unaffiliated
third party for cash consideration of $250,000.
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
April 21, 2021